<DOC>
	<DOCNO>NCT01252979</DOCNO>
	<brief_summary>The current study prospective evaluation ability ketosis shift mitochondrial DNA ( mtDNA ) heteroplasmy subject harbor know mutation mtDNA position 3243 ( A &gt; G ) . Subjects give supplemental medium chain triglyceride ( MCTs ) period 6 month . mtDNA heteroplasmy measure 3 month prior treatment , treatment initiation , 6 month initiation . The primary objective current study determine shift heteroplasmy patient harbor 3243 A &gt; G mtDNA mutation favorable ( high wild-type ) profile state ketosis .</brief_summary>
	<brief_title>Ketones &amp; Mitochondrial Heteroplasmy</brief_title>
	<detailed_description>The current study prospective evaluation ability ketosis shift mitochondrial DNA ( mtDNA ) heteroplasmy subject harbor know pathogenic mutation mtDNA position 3243 ( A &gt; G ) . Subjects induce ketosis administration supplemental medium chain triglyceride ( MCTs ) period 6 month . mtDNA heteroplasmy assess 3 month prior treatment , treatment initiation , 6 month initiation . The primary objective current study determine shift heteroplasmy patient harbor 3243 A &gt; G mtDNA mutation favorable ( high wild-type ) genotypic profile state ketosis .</detailed_description>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>MELAS Syndrome</mesh_term>
	<criteria>1 . Subject inform give ample opportunity consider his/her participation give his/her write consent . 2 . Subject willing able comply trial requirement . 3 . Subject harbor 3243 A &gt; G mtDNA mutation level detectable blood . 4 . Female subject childbearing potential must pregnant . Female subject childbearing potential ( surgically sterile 2 year postmenopausal ) must also agree use appropriate contraceptive method ( abstinence , oral , injectable , implantable , barrier ) duration trial . 5 . Subject must diabetes mellitus . 1 . Subject currently participate participate within last 2 month clinical trial involve treatment mitochondrial disorder MCT supplementation induction ketosis . 2 . Subject medical condition could reasonably exacerbate ketone supplementation ( include diabetes mellitus ) . 3 . Subject unable give reasonable inform consent/assent . 4 . Subject pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>MELAS</keyword>
	<keyword>Ketones</keyword>
	<keyword>Medium Chain Triglycerides</keyword>
	<keyword>MCT oil</keyword>
	<keyword>Mitochondrial Disorder</keyword>
	<keyword>Heteroplasmy</keyword>
	<keyword>3243AG</keyword>
	<keyword>Subject inform give ample opportunity consider his/her participation give his/her write consent .</keyword>
	<keyword>Subject willing able comply trial requirement .</keyword>
	<keyword>Subject harbor 3243 A &gt; G mtDNA mutation level detectable blood .</keyword>
	<keyword>Female subject child-bearing potential must pregnant .</keyword>
	<keyword>Subjects must Diabetes Mellitus .</keyword>
</DOC>